Jeffrey M Peters

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8513341/publications.pdf

Version: 2024-02-01

		15466	12910
165	17,943	65	131
papers	citations	h-index	g-index
166	166	166	14721
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The role of mouse and human peroxisome proliferator-activated receptor- $\hat{l}\pm$ in modulating the hepatic effects of perfluorooctane sulfonate in mice. Toxicology, 2022, 465, 153056.	2.0	6
2	Species Differences between Mouse and Human PPARα in Modulating the Hepatocarcinogenic Effects of Perinatal Exposure to a High-Affinity Human PPARα Agonist in Mice. Toxicological Sciences, 2021, 183, 81-92.	1.4	12
3	Diminished Hepatocarcinogenesis by a Potent, High-Affinity Human PPARα Agonist in <i>PPARA</i> -Humanized Mice. Toxicological Sciences, 2021, 183, 70-80.	1.4	8
4	Targeting Peroxisome Proliferator-Activated Receptor-β/δ (PPARβ/δ) for the Treatment or Prevention of Alcoholic Liver Disease. Biological and Pharmaceutical Bulletin, 2021, 44, 1598-1606.	0.6	4
5	Perfluorooctane sulfonate alters gut microbiota-host metabolic homeostasis in mice. Toxicology, 2020, 431, 152365.	2.0	43
6	Unraveling the role of peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l} (PPAR \hat{l}^2/\hat{l}) expression in colon carcinogenesis. Npj Precision Oncology, 2019, 3, 26.	2.3	8
7	Interplay Between the Host, the Human Microbiome, and Drug Metabolism. Human Genomics, 2019, 13, 27.	1.4	52
8	Regulatory mechanisms mediated by peroxisome proliferatorâ€activated receptorâ€Î²/δ in skin cancer. Molecular Carcinogenesis, 2019, 58, 1612-1622.	1.3	5
9	The PPARα-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions. Archives of Toxicology, 2018, 92, 83-119.	1.9	112
10	Lipid metabolism and lipophagy in cancer. Biochemical and Biophysical Research Communications, 2018, 504, 582-589.	1.0	175
11	The Evolution of Carcinogenesis. Toxicological Sciences, 2018, 165, 272-276.	1.4	35
12	Inhibition of tumorigenesis by peroxisome proliferator-activated receptor (PPAR)-dependent cell cycle blocks in human skin carcinoma cells. Toxicology, 2018, 404-405, 25-32.	2.0	15
13	Molecular Regulation of Carcinogenesis: Friend and Foe. Toxicological Sciences, 2018, 165, 277-283.	1.4	34
14	Peroxisome proliferatorâ€activated receptorâ€ <i>β</i> /i>/ <i>δ</i> modulates mast cell phenotype. Immunology, 2017, 150, 456-467.	2.0	7
15	Peroxisome proliferatorâ€activated receptorâ€î²Ĵſ inhibits human neuroblastoma cell tumorigenesis by inducing p53†and SOX2â€mediated cell differentiation. Molecular Carcinogenesis, 2017, 56, 1472-1483.	1.3	22
16	Four-week dietary supplementation with 10- and/or 15-fold basal choline caused decreased body weight in Sprague Dawley rats. Toxicology and Industrial Health, 2017, 33, 792-801.	0.6	4
17	Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation. Journal of Visualized Experiments, 2017, , .	0.2	10
18	Flipping a citrate switch on liver cancer cells. Journal of Biological Chemistry, 2017, 292, 13902-13903.	1.6	10

#	Article	IF	CITATIONS
19	Editor's Highlight: PPARβ∫δ and PPARγ Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis. Toxicological Sciences, 2017, 159, 436-448.	1.4	14
20	Perfluorooctane Sulfonate-Induced Hepatic Steatosis in Male Sprague Dawley Rats Is Not Attenuated by Dietary Choline Supplementation. Toxicological Sciences, 2017, 160, 284-298.	1.4	15
21	Ligand activation of peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l}' suppresses liver tumorigenesis in hepatitis B transgenic mice. Toxicology, 2016, 363-364, 1-9.	2.0	16
22	Editor's Highlight: Perfluorooctane Sulfonate-Choline Ion Pair Formation: A Potential Mechanism Modulating Hepatic Steatosis and Oxidative Stress in Mice. Toxicological Sciences, 2016, 153, 186-197.	1.4	24
23	Omics Approaches To Probe Microbiota and Drug Metabolism Interactions. Chemical Research in Toxicology, 2016, 29, 1987-1997.	1.7	7
24	Regulation of Cytochrome P450 2B10 (CYP2B10) Expression in Liver by Peroxisome Proliferator-activated Receptor- \hat{l}^2/\hat{l}^2 Modulation of SP1 Promoter Occupancy. Journal of Biological Chemistry, 2016, 291, 25255-25263.	1.6	15
25	The Ron Receptor Tyrosine Kinase Regulates Macrophage Heterogeneity and Plays a Protective Role in Diet-Induced Obesity, Atherosclerosis, and Hepatosteatosis. Journal of Immunology, 2016, 197, 256-265.	0.4	18
26	PPARÎ 2 Î $^{^\prime}$ selectively regulates phenotypic features of age-related macular degeneration. Aging, 2016, 8, 1952-1978.	1.4	32
27	Inhibition of testicular embryonal carcinoma cell tumorigenicity by peroxisome proliferator-activated receptor- $\hat{l}^2\hat{l}$ and retinoic acid receptor-dependent mechanisms. Oncotarget, 2015, 6, 36319-36337.	0.8	9
28	M-CSF from Cancer Cells Induces Fatty Acid Synthase and PPARβ/δ Activation in Tumor Myeloid Cells, Leading to Tumor Progression. Cell Reports, 2015, 10, 1614-1625.	2.9	72
29	Targeting Peroxisome Proliferator-Activated Receptor- $\hat{l}^2\hat{l}$ (PPAR $\hat{l}^2\hat{l}$) for Cancer Chemoprevention. Current Pharmacology Reports, 2015, 1, 121-128.	1.5	20
30	Establishing the Role of PPARÎ 2 / 2 in Carcinogenesis. Trends in Endocrinology and Metabolism, 2015, 26, 595-607.	3.1	69
31	Peroxisome Proliferator-activated Receptor-D (PPARD) Coordinates Mouse Spermatogenesis by Modulating Extracellular Signal-regulated Kinase (ERK)-dependent Signaling. Journal of Biological Chemistry, 2015, 290, 23416-23431.	1,6	17
32	Modulation of aryl hydrocarbon receptor (AHR)-dependent signaling by peroxisome proliferator-activated receptor \hat{l}^2/\hat{l}' (PPAR \hat{l}^2/\hat{l}') in keratinocytes. Carcinogenesis, 2014, 35, 1602-1612.	1.3	24
33	Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPAR $\langle b \rangle \hat{l} \pm \langle b \rangle$) as a case study. Critical Reviews in Toxicology, 2014, 44, 1-49.	1.9	191
34	Activation of Peroxisome Proliferator-Activated Receptor- $\hat{l}^2\hat{l}'$ (PPAR- $\hat{l}^2\hat{l}'$) Inhibits Human Breast Cancer Cell Line Tumorigenicity. Molecular Cancer Therapeutics, 2014, 13, 1008-1017.	1.9	56
35	Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid. Toxicology, 2014, 326, 62-73.	2.0	18
36	The Nuclear Receptor Peroxisome Proliferator-activated Receptor- \hat{l}^2/\hat{l}' (PPAR \hat{l}^2/\hat{l}') Promotes Oncogene-induced Cellular Senescence through Repression of Endoplasmic Reticulum Stress. Journal of Biological Chemistry, 2014, 289, 20102-20119.	1.6	39

#	Article	IF	Citations
37	Aryl Hydrocarbon Receptor Antagonism Attenuates Growth Factor Expression, Proliferation, and Migration in Fibroblast-Like Synoviocytes from Patients with Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 236-245.	1.3	40
38	Targeting Estrogen Receptor- \hat{l}^2 for the Prevention of Nonmelanoma Skin Cancer. Cancer Prevention Research, 2014, 7, 182-185.	0.7	6
39	Cholestasis induces reversible accumulation of periplakin in mouse liver. BMC Gastroenterology, 2013, 13, 116.	0.8	4
40	PPARÎ 2 Î $^\prime$ modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity. Toxicology, 2013, 311, 87-98.	2.0	12
41	A Species Difference in the Peroxisome Proliferator-Activated Receptor α-Dependent Response to the Developmental Effects of Perfluorooctanoic Acid. Toxicological Sciences, 2013, 131, 568-582.	1.4	37
42	Metabolomics. Toxicologic Pathology, 2013, 41, 410-418.	0.9	14
43	Peroxisome Proliferator-Activated Receptor \hat{I}^2/\hat{I}^2 Cross Talks with E2F and Attenuates Mitosis in HRAS-Expressing Cells. Molecular and Cellular Biology, 2012, 32, 2065-2082.	1.1	16
44	Immunomodulatory action of dietary fish oil and targeted deletion of intestinal epithelial cell PPARδin inflammation-induced colon carcinogenesis. American Journal of Physiology - Renal Physiology, 2012, 302, G153-G167.	1.6	22
45	Analysis of the peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l}' (PPAR \hat{l}^2/\hat{l}') cistrome reveals novel co-regulatory role of ATF4. BMC Genomics, 2012, 13, 665.	1.2	40
46	The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nature Reviews Cancer, 2012, 12, 181-195.	12.8	379
47	PPAR action in insulin resistance unraveled by metabolomics: potential clinical implications. Genome Medicine, 2011, 3, 54.	3.6	1
48	Why Toxic Equivalency Factors Are Not Suitable for Perfluoroalkyl Chemicals. Chemical Research in Toxicology, 2011, 24, 1601-1609.	1.7	44
49	PPARÎ 2 Î $^\circ$ Activation Induces Enteroendocrine L Cell GLP-1 Production. Gastroenterology, 2011, 140, 1564-1574.	0.6	55
50	Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l} (PPAR \hat{l}^2/\hat{l}). Drug Discovery Today Disease Mechanisms, 2011, 8, e85-e93.	0.8	29
51	Stable over-expression of PPARÎ 2 Î $^\prime$ and PPARÎ 3 to examine receptor signaling in human HaCaT keratinocytes. Cellular Signalling, 2011, 23, 2039-2050.	1.7	32
52	Dissecting the role of peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l} (PPAR \hat{l}^2/\hat{l}) in colon, breast, and lung carcinogenesis. Cancer and Metastasis Reviews, 2011, 30, 619-640.	2.7	51
53	Functional characterization of peroxisome proliferatorâ€activated receptorâ€Î²Ĵſ expression in colon cancer. Molecular Carcinogenesis, 2011, 50, 884-900.	1.3	34
54	NTPâ€CERHR expert panel report on the developmental toxicity of soy infant formula. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2011, 92, 421-468.	1.4	81

#	Article	IF	Citations
55	Xenobiotic Metabolism, Disposition, and Regulation by Receptors: From Biochemical Phenomenon to Predictors of Major Toxicities. Toxicological Sciences, 2011, 120, S49-S75.	1.4	294
56	Regulation of Squamous Cell Carcinoma Carcinogenesis by Peroxisome Proliferator-Activated Receptors., 2011,, 223-240.		0
57	Regulation of Oligodendrocyte Progenitor Cell Maturation by PPARÎ: Effects on Bone Morphogenetic Proteins. ASN Neuro, 2010, 2, AN20090033.	1.5	19
58	Effect of prenatal peroxisome proliferator-activated receptor \hat{l}_{\pm} (PPAR \hat{l}_{\pm}) agonism on postnatal development. Toxicology, 2010, 276, 79-84.	2.0	14
59	Synthesis of isosteric selenium analog of the PPARÎ 2 Î $^\prime$ agonist GW501516 and comparison of biological activity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4050-4052.	1.0	16
60	Chemoprevention of Chemically Induced Skin Tumorigenesis by Ligand Activation of Peroxisome Proliferatorâ \in "Activated Receptor- \hat{l}^2/\hat{l} " and Inhibition of Cyclooxygenase 2. Molecular Cancer Therapeutics, 2010, 9, 3267-3277.	1.9	23
61	Cellular and Pharmacological Selectivity of the Peroxisome Proliferator-Activated Receptor-β/δ Antagonist GSK3787. Molecular Pharmacology, 2010, 78, 419-430.	1.0	51
62	Ligand Activation of Peroxisome Proliferator–Activated Receptor-β/δ and Inhibition of Cyclooxygenase-2 Enhances Inhibition of Skin Tumorigenesis. Toxicological Sciences, 2010, 113, 27-36.	1.4	31
63	A natural propenoic acid derivative activates peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l} (PPAR \hat{l}^2/\hat{l}). Life Sciences, 2010, 86, 493-498.	2.0	15
64	Ligand activation of peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l} (PPAR \hat{l}^2/\hat{l}) inhibits cell growth in a mouse mammary gland cancer cell line. Cancer Letters, 2010, 288, 219-225.	3.2	20
65	Regulation of Peroxisome Proliferator–Activated Receptor-α by MDM2. Toxicological Sciences, 2009, 108, 48-58.	1.4	23
66	Differential Hepatic Effects of Perfluorobutyrate Mediated by Mouse and Human PPAR-α. Toxicological Sciences, 2009, 110, 204-211.	1.4	34
67	PPARδ is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer. Prostaglandins and Other Lipid Mediators, 2009, 88, 97-100.	1.0	28
68	Sorting out the functional role(s) of peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l}' (PPAR \hat{l}^2/\hat{l}) in cell proliferation and cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1796, 230-241.	3.3	80
69	Regulation of peroxisome proliferatorâ€activated receptorâ€Î²Î´ by the APCĴβâ€CATENIN pathway and nonsteroidal antiinflammatory drugs. Molecular Carcinogenesis, 2009, 48, 942-952.	1.3	33
70	Peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l}' (PPAR \hat{l}^2/\hat{l}') ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology, 2008, 243, 236-243.	2.0	63
71	Effect of ligand activation of peroxisome proliferator-activated receptor-l²/l̂´ (PPARl̂²/l̂´) in human lung cancer cell lines. Toxicology, 2008, 254, 112-117.	2.0	28
72	Quantitative expression patterns of peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l}' (PPAR \hat{l}^2/\hat{l}') protein in mice. Biochemical and Biophysical Research Communications, 2008, 371, 456-461.	1.0	132

#	Article	IF	CITATIONS
73	Regulation of Peroxisome Proliferator-Activated Receptors by E6-Associated Protein. PPAR Research, 2008, 2008, 1-8.	1.1	3
74	Ligand Activation of Peroxisome Proliferator-Activated Receptor- \hat{l}^2/\hat{l} Inhibits Cell Proliferation in Human HaCaT Keratinocytes. Molecular Pharmacology, 2008, 74, 1429-1442.	1.0	55
75	Nrf2- and PPARα-Mediated Regulation of Hepatic Mrp Transporters after Exposure to Perfluorooctanoic Acid and Perfluorodecanoic Acid. Toxicological Sciences, 2008, 106, 319-328.	1.4	96
76	Ligand activation of peroxisome proliferator-activated receptor- $\hat{I}^2\hat{I}$ (PPAR $\hat{I}^2\hat{I}$) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis, 2008, 29, 169-176.	1.3	61
77	Peroxisome Proliferator–Activated Receptor-δAgonist Enhances Vasculogenesis by Regulating Endothelial Progenitor Cells Through Genomic and Nongenomic Activations of the Phosphatidylinositol 3-Kinase/Akt Pathway. Circulation, 2008, 118, 1021-1033.	1.6	85
78	Ligand Activation of Peroxisome Proliferator–Activated Receptor β∫Î (PPARβ∫Î) Attenuates Carbon Tetrachloride Hepatotoxicity by Downregulating Proinflammatory Gene Expression. Toxicological Sciences, 2008, 105, 418-428.	1.4	76
79	Ligand activation of peroxisome proliferator-activated receptor β/Ĩ´ (PPARĨ²/Ĩ´) inhibits chemically induced skin tumorigenesis. Carcinogenesis, 2008, 29, 2406-2414.	1.3	40
80	Mechanistic Evaluation of PPARÎ \pm -Mediated Hepatocarcinogenesis: Are We There Yet?. Toxicological Sciences, 2008, 101, 1-3.	1.4	13
81	Role of peroxisome-proliferator-activated receptor βʃl´ (PPARβʃl´) in gastrointestinal tract function and disease. Clinical Science, 2008, 115, 107-127.	1.8	102
82	A Role for PPARβ/Î în Tumor Stroma and Tumorigenesis. PPAR Research, 2008, 2008, 1-5.	1.1	10
83	Induction of Nuclear Translocation of Constitutive Androstane Receptor by Peroxisome Proliferator-activated Receptor α Synthetic Ligands in Mouse Liver. Journal of Biological Chemistry, 2007, 282, 36766-36776.	1.6	32
84	Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12890-12895.	3.3	198
85	COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARδ activation. Journal of Experimental Medicine, 2007, 204, 2053-2061.	4.2	64
86	Peroxisome proliferator-activated receptor- $\hat{l}^2\hat{l}'$ (PPAR $\hat{l}^2\hat{l}'$) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis, 2007, 28, 2641-2649.	1.3	65
87	PPARÎ \pm and Effects of TCE. Environmental Health Perspectives, 2007, 115, A14-5; authohr reply A15-6.	2.8	0
88	Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARβ/δ gene. International Journal of Oncology, 2007, , .	1.4	6
89	Peroxisome proliferator-activated receptor- $\hat{l}^2\hat{l}$ protects against chemically induced liver toxicity in mice. Hepatology, 2007, 47, 225-235.	3.6	79
90	Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient mice. EMBO Journal, 2007, 26, 3686-3698.	3.5	94

#	Article	IF	Citations
91	Ligand activation of peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l} (PPAR \hat{l}^2/\hat{l}) inhibits cell growth of human N/TERT-1 keratinocytes. Cellular Signalling, 2007, 19, 1163-1171.	1.7	77
92	Sustained formation of \hat{l}_{\pm} -(4-pyridyl-1-oxide)-N-tert-butylnitrone radical adducts in mouse liver by peroxisome proliferators is dependent upon peroxisome proliferator-activated receptor- \hat{l}_{\pm} , but not NADPH oxidase. Free Radical Biology and Medicine, 2007, 42, 335-342.	1.3	10
93	The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l} (PPAR \hat{l}^2/\hat{l}). Free Radical Biology and Medicine, 2007, 42, 1155-1164.	1.3	99
94	PPARÎ 2 /δ Protects Against Experimental Colitis Through a Ligand-Independent Mechanism. Digestive Diseases and Sciences, 2007, 52, 2912-2919.	1.1	45
95	Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARbeta/delta gene. International Journal of Oncology, 2007, 31, 607-11.	1.4	13
96	Modes of Action and Species-Specific Effects of Di-(2-ethylhexyl)Phthalate in the Liver. Critical Reviews in Toxicology, 2006, 36, 459-479.	1.9	225
97	Alterations in Skin and Stratified Epithelia by Constitutively Activated PPARα. Journal of Investigative Dermatology, 2006, 126, 374-385.	0.3	23
98	The role of peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l} in epithelial cell growth and differentiation. Cellular Signalling, 2006, 18, 9-20.	1.7	140
99	PPARδ status and mismatch repair mediated neoplasia in the mouse intestine. BMC Cancer, 2006, 6, 113.	1.1	8
100	Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor- $\hat{l}^2\hat{l}$ (PPAR $\hat{l}^2\hat{l}$). Carcinogenesis, 2006, 27, 1105-1112.	1.3	25
101	The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR). Toxicological Sciences, 2006, 90, 269-295.	1.4	232
102	The Aryl Hydrocarbon Receptor Directly Regulates Expression of the Potent Mitogen Epiregulin. Toxicological Sciences, 2006, 89, 75-82.	1.4	68
103	Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. Journal of Lipid Research, 2006, 47, 2028-2041.	2.0	279
104	Ligand Activation of Peroxisome Proliferator–Activated Receptor β Inhibits Colon Carcinogenesis. Cancer Research, 2006, 66, 4394-4401.	0.4	125
105	PPARÂ regulates glucose metabolism and insulin sensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3444-3449.	3.3	451
106	Protective effects of a peroxisome proliferator-activated receptor- \hat{l}^2/\hat{l} agonist in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2005, 168, 65-75.	1.1	114
107	Peroxisome proliferator-activated receptor- \hat{l}_{\pm} and liver cancer: where do we stand?. Journal of Molecular Medicine, 2005, 83, 774-785.	1.7	229
108	Peroxisome Proliferator-activated Receptor- $\hat{I}^2 \hat{I}$ Inhibits Epidermal Cell Proliferation by Down-regulation of Kinase Activity. Journal of Biological Chemistry, 2005, 280, 9519-9527.	1.6	81

#	Article	IF	Citations
109	Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor \hat{l}_{\pm} Modulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 585-591.	1.1	116
110	Differences in cell proliferation in rodent and human hepatic derived cell lines exposed to ciprofibrate. Cancer Letters, 2005, 222, 217-226.	3.2	8
111	Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity. Archives of Biochemistry and Biophysics, 2005, 442, 59-71.	1.4	39
112	Peroxisome Proliferator-activated Receptor \hat{l}^2 (\hat{l})-dependent Regulation of Ubiquitin C Expression Contributes to Attenuation of Skin Carcinogenesis. Journal of Biological Chemistry, 2004, 279, 23719-23727.	1.6	85
113	PPARÂ influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis, 2004, 25, 1747-1755.	1.3	105
114	Expression of Base Excision DNA Repair Genes Is a Sensitive Biomarker for in Vivo Detection of Chemical-induced Chronic Oxidative Stress. Cancer Research, 2004, 64, 1050-1057.	0.4	89
115	Reduced Adiposity and Liver Steatosis by Stearoyl-CoA Desaturase Deficiency Are Independent of Peroxisome Proliferator-activated Receptor-α. Journal of Biological Chemistry, 2004, 279, 35017-35024.	1.6	108
116	Role of peroxisome proliferator-activated receptor-Â (PPARÂ) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis, 2004, 26, 219-227.	1.3	119
117	PPARβ/δ potentiates PPARγâ€stimulated adipocyte differentiation. FASEB Journal, 2004, 18, 1477-1479.	0.2	93
118	Peroxisome Proliferator-activated Receptor \hat{l}^2/\hat{l} Regulates Very Low Density Lipoprotein Production and Catabolism in Mice on a Western Diet. Journal of Biological Chemistry, 2004, 279, 20874-20881.	1.6	85
119	Activation of Mouse and Human Peroxisome Proliferator-Activated Receptors (PPARs) by Phthalate Monoesters. Toxicological Sciences, 2004, 82, 170-182.	1.4	185
120	Peroxisome proliferator–activated receptor-δattenuates colon carcinogenesis. Nature Medicine, 2004, 10, 481-483.	15.2	198
121	PPARδ status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene, 2004, 23, 8992-8996.	2.6	105
122	Peroxisome proliferator-activated receptor α protects against alcohol-induced liver damage. Hepatology, 2004, 40, 972-980.	3.6	32
123	Peroxisome proliferator-activated receptor ? protects against alcohol-induced liver damage. Hepatology, 2004, 40, 972-980.	3.6	214
124	Bezafibrate is a dual ligand for PPARÎ \pm and PPARÎ 2 : studies using null mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1632, 80-89.	1.2	99
125	PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance. Critical Reviews in Toxicology, 2003, 33, 655-780.	1.9	549
126	Comprehensive gene expression analysis of peroxisome proliferator-treated immortalized hepatocytes: identification of peroxisome proliferator-activated receptor alpha-dependent growth regulatory genes. Cancer Research, 2003, 63, 5767-80.	0.4	27

#	Article	IF	CITATIONS
127	Targeted disruption of peroxisomal proliferator-activated receptor \hat{l}^2 (\hat{l}) results in distinct gender differences in mouse brain phospholipid and esterified FA levels. Lipids, 2002, 37, 495-500.	0.7	21
128	Hepatic regeneration in peroxisome proliferator-activated receptor α-null mice after partial hepatectomy. Hepatology Research, 2002, 22, 52-57.	1.8	38
129	Pretreatment with troglitazone decreases lethality during endotoxemia in mice. Journal of Endotoxin Research, 2002, 8, 307-314.	2.5	14
130	Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)α and PPARβ mutant mice. Journal of Cell Biology, 2001, 154, 799-814.	2.3	388
131	Adaptive Increase in Pyruvate Dehydrogenase Kinase 4 during Starvation Is Mediated by Peroxisome Proliferator-Activated Receptor \hat{l}_{\pm} . Biochemical and Biophysical Research Communications, 2001, 287, 391-396.	1.0	186
132	Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor α-null mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2001, 1533, 233-242.	1.2	131
133	Phthalates Rapidly Increase Production of Reactive Oxygen Species in Vivo: Role of Kupffer Cells. Molecular Pharmacology, 2001, 59, 744-750.	1.0	86
134	Peroxisome Proliferator-Activated Receptors (PPAR) and the Mitochondrial Aldehyde Dehydrogenase (ALDH2) Promoter In Vitro and In Vivo. Alcoholism: Clinical and Experimental Research, 2001, 25, 945-952.	1.4	18
135	Peroxisome Proliferator-activated Receptor-α Regulates Lipid Homeostasis, but Is Not Associated with Obesity. Journal of Biological Chemistry, 2001, 276, 39088-39093.	1.6	119
136	Peroxisome Proliferator-activated Receptor \hat{l}_{\pm} Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil. Journal of Biological Chemistry, 2001, 276, 4634-4639.	1.6	70
137	PPARα-Dependent Induction of Liver Microsomal Esterification of Estradiol and Testosterone by a Prototypical Peroxisome Proliferator. Endocrinology, 2001, 142, 3554-3557.	1.4	12
138	Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARα and TNFα. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2000, 448, 193-200.	0.4	59
139	Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure. American Journal of Physiology - Renal Physiology, 2000, 278, F667-F675.	1.3	144
140	Evidence for Peroxisome Proliferator-Activated Receptor (PPAR)α-Independent Peroxisome Proliferation: Effects of PPARγ/δ-Specific Agonists in PPARα-Null Mice. Molecular Pharmacology, 2000, 58, 470-476.	1.0	55
141	Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor $\hat{l}^2(\hat{l})$. Molecular and Cellular Biology, 2000, 20, 5119-5128.	1.1	615
142	Peroxisome proliferator-activated receptor \hat{A} is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis, 2000, 21, 823-826.	1.3	122
143	Influence of peroxisome proliferator-activated receptor \hat{l}_{\pm} on ubiquinone biosynthesis. Journal of Molecular Biology, 2000, 297, 607-614.	2.0	42
144	Evidence against the peroxisome proliferator-activated receptor \hat{l}_{\pm} (PPAR \hat{l}_{\pm}) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription. Journal of Lipid Research, 2000, 41, 742-751.	2.0	52

#	Article	IF	Citations
145	Involvement of the peroxisome proliferator-activated receptor \hat{l}_{\pm} in regulating long-chain acyl-CoA thioesterases. Journal of Lipid Research, 2000, 41, 814-823.	2.0	46
146	The human peroxisome proliferator-activated receptor ?? gene: identification and functional characterization of two natural allelic variants. Pharmacogenetics and Genomics, 2000, 10, 321-333.	5.7	128
147	CYP2E1 is not involved in early alcohol-induced liver injury. American Journal of Physiology - Renal Physiology, 1999, 277, G1259-G1267.	1.6	89
148	Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor-. Blood, 1999, 93, 2991-2998.	0.6	127
149	Metabolism of Chloroform by Cytochrome P450 2E1 Is Required for Induction of Toxicity in the Liver, Kidney, and Nose of Male Mice. Toxicology and Applied Pharmacology, 1999, 160, 120-126.	1.3	107
150	Peroxisomal and Mitochondrial Fatty Acid \hat{l}^2 -Oxidation in Mice Nullizygous for Both Peroxisome Proliferator-activated Receptor \hat{l}^2 and Peroxisomal Fatty Acyl-CoA Oxidase. Journal of Biological Chemistry, 1999, 274, 19228-19236.	1.6	210
151	Peroxisome Proliferator-activated Receptor $\hat{l}\pm$ Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF- \hat{l}° B and AP-1. Journal of Biological Chemistry, 1999, 274, 32048-32054.	1.6	982
152	Effect of Peroxisome Proliferator-Activated Receptor Alpha Activators on Tumor Necrosis Factor Expression in Mice during Endotoxemia. Infection and Immunity, 1999, 67, 3488-3493.	1.0	77
153	In Vivo Regulation of Hepatitis B Virus Replication by Peroxisome Proliferators. Journal of Virology, 1999, 73, 10377-10386.	1.5	51
154	Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting. Journal of Clinical Investigation, 1999, 103, 1489-1498.	3.9	1,423
155	Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor-. Blood, 1999, 93, 2991-2998.	0.6	39
156	Mechanism of Action of the Nongenotoxic Peroxisome Proliferators: Role of the Peroxisome Proliferator-Activated Receptor A. Journal of the National Cancer Institute, 1998, 90, 1702-1709.	3.0	282
157	Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor \hat{I}_{\pm} and \hat{I}_{3} Activators in a Tissue- and Inducer-specific Manner. Journal of Biological Chemistry, 1998, 273, 16710-16714.	1.6	475
158	Receptor and Nonreceptor-Mediated Organ-Specific Toxicity of Di(2-ethylhexyl)phthalate (DEHP) in Peroxisome Proliferator-Activated Receptorα-Null Mice. Toxicologic Pathology, 1998, 26, 240-246.	0.9	236
159	Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα). Journal of Biological Chemistry, 1998, 273, 5678-5684.	1.6	777
160	Polyunsaturated Fatty Acid Suppression of Hepatic Fatty Acid Synthase and S14 Gene Expression Does Not Require Peroxisome Proliferator-activated Receptor α. Journal of Biological Chemistry, 1997, 272, 26827-26832.	1.6	244
161	Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice. Journal of Biological Chemistry, 1997, 272, 27307-27312.	1.6	388
162	PPARα Mediates Peroxisome Proliferator-Induced Transcriptional Repression of Nonperoxisomal Gene Expression in Mouse. Biochemical and Biophysical Research Communications, 1997, 230, 155-158.	1.0	35

#	Article	IF	CITATIONS
163	Di(2-Ethylhexyl) phthalate induces a functional zinc deficiency during pregnancy and teratogenesis that is independent of peroxisome proliferator-activated receptor-α., 1997, 56, 311-316.		79
164	The PPARα–leukotriene B4 pathway to inflammation control. Nature, 1996, 384, 39-43.	13.7	1,329
165	The Effect of Valproic Acid on 65Zn Distribution in the Pregnant Rat. Journal of Nutrition, 1989, 119, 607-611.	1.3	49